

43 iAP20 Rec'd PCT/PTO 14 JUN 2006

AMENDED CLAIMS

[received by the International Bureau on 28 September 2005 (28.09.05);
original claims 5, 30, 42, 44, 46 amended; Claim 50 added as new;
other claims remain unchanged (pages 6)]

- 5 1. A method for treating an ophthalmologic condition, the method comprising steps
of:
 providing a contact lens;
 providing a pharmaceutical composition suitable for ocular administration,
 wherein the pharmaceutical composition comprises hyaluronidase or collagenase;
10 applying contact lens to eye of patient suffering from an ophthalmologic
 condition; and
 applying pharmaceutical composition to the eye of patient.
2. A method for treating an ophthalmologic condition by inducing changes in the
15 physiology and anatomy of cornea, the method comprising steps of:
 inducing a change in the corneal power by using molding contact lenses and a
 pharmaceutical composition by changing the radius of curvature of the anterior surface of
 both eyes, wherein the pharmaceutical composition comprises hyaluronidase or
 collagenase.
- 20 3. A method for treating an ophthalmologic condition by inducing changes in the
 physiology and anatomy of cornea, the method comprising steps of:
 inducing a change in the corneal power by using molding contact lenses and a
 pharmaceutical composition by changing the radius of curvature of the anterior surface in
25 only one eye, wherein the pharmaceutical composition comprises hyaluronidase or
 collagenase.
4. A method for the treatment of an ophthalmologic condition by inducing changes
 in the physiology and anatomy of cornea, the method comprising steps of:
30 calculating the corneal power considering the sphere (myopia) and cylinder
 (astigmatism) myopics within a range to be able to correct the near vision without

diminishing substantially the far vision;

considering the best axis of astigmatism for each eye that a patient requires for the near vision so that the change induced in the corneal power along with its axis will be that required for the visual system of the patient;

5 allowing the patient to guide the necessary changes in the corneal power whereby good near vision is obtained;

using the molding contact lenses to change the surface of the cornea; and

administering a pharmaceutical composition to the eye, wherein the composition comprises hyaluronidase or collagenase.

.10

5. The method of claim 4, wherein the sphere (myopia) ranges from -0.100 D to -0.999 D.

15

6. The method of claim 4, wherein the cylinder (astigmatism) ranges from -0.100 D to -0.999 D.

20

7. The method of claim 4, wherein the hypermetropia ranges from +0.100 D to +0.999 D, and the cylinder (astigmatism) ranges from -0.100 D to -0.999 D.

8.

The method of claim 1, 2, 3, or 4, wherein the contact lenses are commercially available.

9.

The method of claim 1, 2, 3, or 4, wherein the contact lens is not custom made.

25

10. The method of claim 1, 2, 3, or 4, wherein the contact lens is not specially designed for orthokeratology.

11. The method of claim 1, 2, 3, or 4, wherein the contact lens is an extended wear contact lens.

30

12. The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is a

combination of agents selected from the group consisting of enzymes, anesthetics, vitamins, antibiotics, and anti-inflammatory agents.

13. The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition
5 comprises hyaluronase and collagenase.

14. The method of claim 13, wherein the pharmaceutical composition additionally
comprises a vehicle selected from the group consisting of methylcellulose, cellulose, and
polyvinylalcohol.

10 15. The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is in
the form of eyedrops.

15 16. The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is in
the form of a gel.

17. The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is
hypertonic.

20 18. The method of claim 1, 2, 3, or 4, wherein the pharmaceutical composition is
hypotonic.

19. The method of claim 1, 2, 3, or 4, whereby the treatment results in correction of
the ophthalmologic condition for at least 7 days.

25 20. The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction
of the ophthalmologic condition for at least 6 months.

21. The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction
30 of the ophthalmologic condition for at least 1 years.

22. The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of up to 3 diopters of refractive error without surgery.
 23. The method of claim 1, 2, 3, or 4, whereby the treatment results in the correction of up to 4 diopters of refractive error without surgery.
 24. The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is presbyopia.
- 10 25. The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is myopia.
26. The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is hyperopia.
- 15 27. The method of claim 1, 2, 3, or 4, wherein the ophthalmologic condition is astigmatism.
28. A pharmaceutical composition comprising:
- 20 (1) an enzyme selected from the group consisting of hyaluronidase and collagenase; and
- (2) at least one agent selected from the group consisting of enzymes, anesthetics, vitamins, antibiotics, lubricants, anti-inflammatory agents, and vehicles.
- 25 29. The pharmaceutical composition of claim 28, wherein the composition is hypertonic.
30. The pharmaceutical composition of claim 28, wherein the composition is hypotonic.
- 30 31. The pharmaceutical composition of claim 28, wherein the composition is suitable

for ocular administration.

32. The pharmaceutical composition of claim 28, wherein the composition is liquid.
- 5 33. The pharmaceutical composition of claim 28, wherein the composition is a semi-solid gel.
34. The pharmaceutical composition of claim 28, wherein the composition comprises a polymer as a vehicle.
- 10 35. The pharmaceutical composition of claim 34, wherein the polymer is selected from the group consisting of methylcellulose and polyvinylalcohol.
- 15 36. The pharmaceutical composition of claim 28, wherein the composition comprises hyaluronidase.
37. The pharmaceutical composition of claim 28, wherein the composition comprises collagenase.
- 20 38. The pharmaceutical composition of claim 28, wherein the composition comprises collagenase and hyaluronidase.
39. The pharmaceutical composition of claim 28, wherein the composition comprises an anesthetic, an antibiotic, an anti-inflammatory agent, an anti-allergic agent, vitamin A, 25 hyaluronidase, carbamide, and a vasoconstrictor.
40. The pharmaceutical composition of claim 39 further comprising collagenase.
41. The pharmaceutical composition of claim 28, wherein the composition comprises 30 at least three agents selected from the group consisting of an anesthetic, an antibiotic, an anti-inflammatory agent, an anti-allergic agent, vitamin A, hyaluronidase, carbamide, a

cytokinase, and a vasoconstrictor.

42. The pharmaceutical composition of claim 28, wherein the composition comprises at least four agents selected from the group consisting of an anesthetic, an antibiotic, an

5 anti-inflammatory agent, an anti-allergic agent, vitamin A, hyaluronidase, carbamide, a cytokinase, and a vasoconstrictor.

43. A pharmaceutical composition comprising:

hyaluronidase in the range of 0.1% to 5%;

10 collagenase in the range of 0.1% to 6%; and

a vehicle selected from the group consisting of methylcellulose and polyvinylalcohol.

44. The composition of claim 43, wherein the composition is hypertonic.

15

45. The composition of claim 43, wherein the composition is hypotonic.

20

46. The composition of claim 43 further comprising at least one agent selected from the group consisting of anesthetics, antibiotics, anti-inflammatory agents, anti-allergic agents, vitamin A, carbamide, cytokinase, and vasoconstrictors.

47. A kit comprising contact lenses and a pharmaceutical composition, wherein the pharmaceutical composition comprises hyaluronidase or collagenase.

25 48. The kit of claim 47 further comprising instructional materials.

49. The kit of claim 47 further comprising contact lens cleaning supplies.

50. The pharmaceutical composition of claim 28, wherein the composition is a spray.